Drug glossary Drug

KZR-261

A drug being studied in colorectal cancer trials. It appears in 1 clinical trial.

Oral Undisclosed kinase target
See its trials
United States Investigational
European Union Investigational
Spain Not available

What it is

KZR-261 is an oral small molecule inhibitor designed to target solid tumors including colorectal cancer. This compound is being developed as a targeted therapy for patients with advanced solid malignancies who have limited treatment options. Based on its development profile, KZR-261 appears to be part of a tumor-agnostic approach, meaning it targets specific molecular pathways present across different cancer types rather than being specific to colorectal cancer alone.

How it works

KZR-261 likely functions by inhibiting specific protein kinases or signaling pathways that are critical for tumor cell survival and proliferation. The exact molecular target and mechanism of action have not been fully disclosed in publicly available information, but it appears to interfere with cellular processes that drive cancer growth and metastasis.

Molecular targets

Common side effects

FatigueNauseaDiarrheaDecreased appetiteRashElevated liver enzymesNeutropeniaThrombocytopenia

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.